Acadia Pharmaceuticals Inc.

Allan K Uldam

Carl-Magnus A Andersson

Robert E Davis

Mark R Brann

David M Weiner

Eva Louise Hansen

Glenn Croston

Niels Skjaerbaek

Tracy Spalding

Bo Lennart M Friberg

Norman Nash

Carl-Magnus A Anderson

MDavid Weiner

Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

Methods of treatment using selective 5-HT2A inverse agonists

Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

Azacyclic compounds

Growing community of inventors

Vaerloese, Denmark

Allan K Uldam